Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of sufferers with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some clients that are labeled as obtaining gentle or moderate illness may have a serious bleeding phenotype, https://hemgenix59257.blognody.com/39452609/hemgenix-secrets